Repiimune Rpl-002-18
Posted Date: Jul 8, 2020
- Investigator: Rekha Chaudhary
- Specialties: Cancer, Oncology, Skin Cancer
- Type of Study: Drug
The goal of this study is to estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), as assessed by overall response rate(ORR).
Criteria:
To Be Eligible: Must Have Histologically Confirmed Diagnosis Of Cscc That Is Locally Advanced Or Metastatic, Ecog =1, Life Expectancy >12 Weeks, Po2 = 92% On Room Air, No Active Or Previous Infection Or Illness That Could Impact Study Treatment, No Hypersensitivity To Study Drugs Or Excipients, No Other Malignancy Within 3 Years
Keywords:
Cscc, Cutaneous Squamous Cell Carcinoma
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com